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Type 1 fimbriated Escherichia coli represents the
most common human uropathogen, owing much of its
virulence to invasion of the uroepithelium, which is
highly impermeable due to the preponderance of uro-
plakins and highly ordered lipid components. We sought
to elucidate the molecular basis for E. coli invasion of
the bladder epithelium by employing human 5637 blad-
der epithelial cells, and we found the following: (i) in-
tracellular E. coli associated with caveolae and lipid raft
components; (ii) RNAi reduction of caveolin-1 expres-
sion inhibited bacterial invasion; (iii) a signaling mole-
cule required for E. coli invasion was located in lipid
rafts and physically associated with caveolin-1; (iv) bac-
terial invasion was inhibited by lipid raft disrupting/
usurping agents. In the mouse bladder, the E. coli type 1
fimbrial receptor, uroplakin Ia, was located in lipid
rafts, and lipid raft disruptors inhibited E. coli invasion.
Cumulatively, E. coli uroepithelial invasion occurs
through lipid rafts, which, paradoxically, contribute to
bladder impermeability.
Urinary tract infections (UTIs),1 one of the most common
bacterial infections in humans, cause 6–7 million hospital vis-
its per year (1, 2). The most common causative agent of UTIs is
uropathogenic Escherichia coli (2, 3), which expresses filamen-
tous organelles of adhesion called type 1 fimbriae (4). These
fimbriae mediate bacterial adherence to the uroepithelium,
promoting sustained colonization of this normally sterile body
site (5). An important characteristic of UTIs is the frequency of
recurrence among women (6), as up to 25% of women who
experience a first UTI will have a second infection within 6
months (7). Historically, recurrence was thought to be initiated
by a reinfection of the urinary tract from a reservoir of uro-
pathogenic bacteria located in the gastrointestinal tract (8).
However, recently it has been shown that E. coli can survive for
many weeks in the bladders of mice, without bacteriuria (9, 10).
This establishment of a quiescent bladder infection has been
linked to the ability of type 1 fimbriated E. coli to invade and
persist within bladder epithelial cells (BEC). Invasion was
mediated by bacterial type 1 fimbriae (11), and in their intra-
cellular location, the bacteria were presumably inaccessible to
immune cells of the host as well as antibiotics (9, 10). The
ability of E. coli to invade and persist within BEC could explain
the frequent recurrence of E. coli infections of the bladder and
their apparent resistance to antibiotic therapy.
It is interesting that the typically noninvasive uropathogenic
E. coli is able to invade the bladder epithelium, considering the
highly impermeable barrier it presents to its luminal contents
(12, 13). It has been shown recently that the high impermeabil-
ity of the urothelium arises largely from the presence of scallop-
shaped plaques on the apical surface of the superficial BEC,
also known as the asymmetric unit membrane, which line the
lumen of the bladder (13, 14). These plaques are composed of
four subunits, known as uroplakins (UP): UPIa, the host recep-
tor for type 1 fimbriated E. coli (15), and UPIb, which pair with
UPII and UPIII, respectively (16). The composition of the lipids
associated with the urothelial plaques is also believed to play a
large role in determining the permeability barrier of the uro-
epithelium (14, 17). Purified urothelial plaques are rich in both
cholesterol and sphingolipids (18, 19), which leads to a more
ordered lipid structure, lowering membrane fluidity and per-
meability and favoring microdomain formation (20–22). Thus,
the urothelial plaques work in conjunction with associated
specialized lipid microdomains to mediate the high imperme-
ability of the uroepithelium. Cholesterol- and sphingolipid-en-
riched microdomains have recently been the focus of much
study and are often referred to as lipid rafts (20, 22, 23).
Lipid rafts are highly ordered regions of the plasma mem-
branes enriched in not only cholesterol and sphingolipids but
also glycolipids and glycosylphosphatidylinositol-anchored
molecules and may contain a 22-kDa protein, caveolin-1 (20,
23, 24). A subtype of lipid rafts, caveolae, has a distinct cave-
like morphology in the plasma membrane (23, 25). Lipid rafts
have been implicated in signal transduction as a large number
of signaling molecules aggregate within them (20, 23, 24).
These microdomains also possess a versatile endocytic capacity
that has been implicated recently in microbial pathogenesis as
demonstrated by their ability to mediate the entry of viruses,
bacteria, and even large parasites into host cells (25, 26). Par-
adoxically, E. coli may be using the very same structures that
mediate the highly impermeable nature of the uroepithelium,
namely urothelial plaques (specifically UPIa) and the choles-
terol/sphingolipid-rich membrane microdomains associated
with them, to penetrate the uroepithelial barrier. We tested
this hypothesis by investigating the role of lipid rafts in type 1
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fimbriated E. coli invasion of BEC, as elucidation of the molec-
ular aspects of E. coli entry into BEC could lead to the devel-
opment of effective strategies to prevent the emergence and
recurrence of UTIs.
EXPERIMENTAL PROCEDURES
Bacteria and Cell Lines—E. coli strain ORN103 (27), containing a
complete deletion of the type 1 fimbrial gene cluster, was transformed
with plasmid pSH2 (type 1 fimbrial gene cluster, chloramphenicol re-
sistance) (27) or plasmid pREP4 (kanamycin resistance) (Qiagen, Va-
lencia, CA). Bacteria were grown in 10 ml of static Luria-Bertani (LB)
broth with the appropriate antibiotics for 24 h prior to use. Uropatho-
genic E. coli J96 (28) was grown in 10 ml of static Luria-Bertani (LB)
broth for 24 h in the absence of antibiotics. Type 1 fimbrial expression
was confirmed by mannose-sensitive agglutination of baker’s yeast.
Listeria monocytogenes was grown overnight in brain heart infusion
broth (BD Biosciences). The human bladder epithelial cell line 5637
(ATCC HTB-9) was grown in RPMI 1640 (Invitrogen) supplemented
with 10% fetal bovine serum (HyClone, Logan, UT), 2.0 g/liter sodium
bicarbonate, 0.3 g/liter L-glutamine, 2.5 g/liter glucose, 10 mM HEPES,
and 1 mM sodium pyruvate. Cells were cultured at 37 °C with 5% CO2.
5637 BEC Uroplakin Ia Expression—5637 BEC lysates (8.0  106
cells) were made in 400 l of 2 Laemmli sample buffer (Bio-Rad) and
either boiled for 5 min or allowed to remain at room temperature (RT)
for 30 min before SDS-PAGE (45 l of each sample), transfer to a
polyvinylidene difluoride membrane, and immunoblotting with a UPIa-
specific polyclonal antibody (Santa Cruz Biotechnology, Santa
Cruz, CA).
In Vitro Bacterial Invasion Assays—5637 bladder epithelial cells
were seeded into 96-well plates and grown to confluence. Bladder cells
were infected at a multiplicity of infection of 50–100 bacteria per host
cell by the addition of 100 l of bacteria diluted in serum-free cell
culture medium containing 10 mg/ml bovine serum albumin (Sigma),
A600 0.05. Plates were centrifuged for 5 min at 600  g to accelerate
bacterial contact with host cells. Plates were then incubated at 37 °C for
2 h, and the medium was replaced with fresh culture medium contain-
ing 100 g/ml of the membrane-impermeable antibiotic gentamicin
(Invitrogen) to kill extracellular bacteria. Incubation was continued for
an additional 1 h, after which each well was washed three times with
PBS and the cells were lysed by the addition of 100 l of 0.1% Triton
X-100 in PBS and plated onto LB agar plates with chloramphenicol
for E. coli ORN103(pSH2) or brain heart infusion agar plates for
L. monocytogenes.
To test the effect of specific caveolar disruptors/usurpers on bacterial
invasion, methyl--cyclodextrin (1, 5, or 10 mM, Sigma) along with
lovastatin (10 M) in serum-free medium was added to the cells for 30
min prior to infection. The cells were washed three times to remove the
methyl--cyclodextrin, and the medium was replaced with bacteria-
containing medium along with 10 M lovastatin. Nystatin (5 mg/ml
stock in Me2SO, Sigma) was added to the cells at a concentration of 50
g/ml in serum-free medium for 30 min prior to infection. Nystatin was
removed by washing three times, and the cells were infected as before.
The B subunit of cholera toxin (CTB, Sigma) was preincubated with the
cells for 30 min before infection at a concentration of 20 g/ml and
remained on the cells throughout the invasion assay. The viability of
the bladder cells was not affected by any of the treatments used as
determined by trypan blue exclusion. The MTT adherence assay was
performed as follows. 5637 cells were plated overnight onto 96-well
plates and then incubated with 0, 1, 5, or 10 mM methyl--cyclodextrin
for 30 min as above and then fixed overnight with 2.5% paraformalde-
hyde. The monolayers were washed three times with sterile PBS and
pretreated for 1 h at RT with blocking buffer (3% bovine serum albumin
in PBS). 100 l of ORN103(pSH2) (A600 1.0) in PBS was incubated
with the monolayers for 1 h at RT. Nonadherent bacteria were removed
by washing the cell monolayers three times with PBS. Fifty l of LB
was applied to each monolayer and incubated for 15 min at 37 °C. MTT
(Sigma) was dissolved in PBS at 2 mg/ml, filter-sterilized, and stored at
4 °C until use. Fifty l of 2 mg/ml MTT was added to all wells, and the
plates were incubated for 15 min at 37 °C to allow reduction of MTT to
formazan by live bacteria. 150 l of isopropyl alcohol and hydrochloric
acid (at a ratio of 24:1) was added to each well to solubilize the formazan
and the absorbance was measured at 450 nm using a Tecan Sunrise
remote microplate reader.
Bacterial Invasion of Mouse Bladder Epithelium in Vivo—For quan-
titative determination of bacterial invasion, 8-week-old female BALB/c
mice were anesthetized with pentobarbital sodium and inoculated tran-
surethrally with 50 l of an E. coli J96 bacterial suspension (1.0  108
colony-forming units) or a L. monocytogenes bacterial suspension
(1.0  107 colony-forming units) suspended in PBS with or without 25
mM methyl--cyclodextrin. After 1 h, bladders were aseptically re-
moved, bisected, and incubated for 1 h in culture media with 100 g/ml
gentamicin followed by homogenization in 1 ml of sterile 0.1% Triton
X-100. Serial dilutions of the homogenates were plated onto MacConkey
agar plates (for E. coli J96) or brain heart infusion agar plates (for
L. monocytogenes). Methyl--cyclodextrin had no effect on bacterial
viability as determined by colony counts with or without a 60-min
incubation in 25 mM methyl--cyclodextrin.
Sucrose Density Fractionation of Infected Bladder Epithelial Cells—
Bladder epithelial cells were grown to confluence on OmniTray tissue
culture plates (growth area 110 cm2, Nalge Nunc International, Roch-
ester, NY). Three plates were infected with FITC-labeled E. coli
ORN103(pSH2) in 15 ml of serum-free medium (1  109–2  109
bacteria per plate) for 2 h. Infected plates, along with three uninfected
plates, were washed five times with ice-cold PBS and scraped off the
plates using a rubber policeman in 1 ml of homogenization buffer (10
mM Tris (pH 7.2), 2 mM EDTA, 1 mM PMSF, and a 1:100 dilution of
mammalian protease inhibitor mixture (Sigma)). The cell suspension
was then passed 20 times through a 27-gauge needle, brought to 45%
sucrose by the addition of an equal volume of 90% sucrose, and then
overlaid with 2 ml each of 35, 25, 15, and 5% sucrose. The gradients
were centrifuged for 18 h at 39,000 rpm in a SW41Ti rotor (Beckman
Instruments, Palo Alto, CA), and 10 equal fractions were collected from
the top of each gradient and assayed for caveolin-1 by Western blotting
using polyclonal anti-caveolin-1 antibody (Transduction Laboratories,
San Diego) and a goat anti-rabbit IgG conjugated to horseradish per-
oxidase (Sigma). The fractions were also assayed for fluorescence using
a fluorometer.
Fluorescent Microscopy—5637 bladder epithelial cells were seeded
onto 12-mm diameter glass coverslips placed into the wells of a 24-well
plate and grown overnight. The cells were infected with ORN103(pSH2)
as in the invasion assays. The infected cells were incubated at 37 °C for
1–2 h, washed four times with PBS to remove unbound bacteria (fol-
lowed by an additional 1-h incubation with 20 g/ml FITC-CTB (Sigma)
for the cells to be examined for GM1 labeling), and fixed overnight in
2.5% paraformaldehyde in PBS. To label cholesterol, the cells were
incubated with 200 g/ml of the UV fluorescent cholesterol-binding
fungal toxin filipin (Sigma) in PBS for 30 min. To examine caveolin-1
labeling, 5637 cells grown on coverslips as above were infected with the
uropathogenic E. coli J96 for 1–2 h as in the invasion assays, washed
three times with PBS, and fixed overnight with 2.5% paraformalde-
hyde. After removing the fixative, the cells were permeabilized with
0.1% Triton X-100 (Sigma), and caveolin-1 was then labeled using
polyclonal anti-caveolin-1 antibody followed with goat anti-rabbit Alexa
Fluor 488 F(ab)2 (Molecular Probes). Coverslips were examined using
a Nikon Eclipse TE200 microscope with a 4,6-diamidino-2-phenylindole
filter set to examine filipin labeling and a fluorescein filter set to
examine GM1 and caveolin-1 labeling.
Lipid Raft Purification—5637 BEC lipid rafts were purified using a
method described previously with some modifications (29). Briefly, 5637
BEC grown to confluency on OmniTray tissue culture plates (growth
area 110 cm2, Nalge Nunc International) were left untreated or
treated with 10 mM methyl--cyclodextrin in serum-free RPMI 1640
(Invitrogen) at 37 °C for 1 h. Treated and untreated cells (two tissue
culture plates per condition) were washed three times with ice-cold PBS
and removed from the plates using rubber policeman in 3 ml of ice-cold
PBS per plate. Treated and untreated cells were then collected by
centrifugation, and each cell pellet was resuspended in 2 ml of ice-cold
carbonate buffer (500 mM Na2CO3 (pH 11.00), 1 mM EDTA, 1 mM PMSF,
and a 1:100 dilution of mammalian protease inhibitor mixture (Sigma)).
The cells were homogenized by passing through a 21-guage needle 20
times, sonicated in an ice bath for 5 min, and passaged through a
21-guage needle an additional 20 times. The samples were brought to
45% sucrose by the addition of an equal volume of 90% sucrose in MBS
(25 mM MES (Sigma), 75 mM NaCl, pH 6.8) and then overlaid with 4 ml
each of 35 and 5% sucrose in MBS. The gradients were centrifuged for
18 h at 39,000 rpm in a SW41Ti rotor (Beckman Instruments, Palo Alto,
CA), and 12 equal fractions (1 ml each) were collected from the top of
each gradient and assayed for Rac1 and caveolin-1 by Western blotting
using monoclonal anti-Rac1 (Transduction Laboratories) or polyclonal
anti-caveolin-1 antibody.
Lipid rafts were purified from BALB/c mouse bladders as follows.
Bladders from 15 BALB/c female mice were removed and washed briefly
in ice-cold PBS, before brief homogenization in a Potter-Elvehjem tissue
grinder (Kontes Glass Co., Vineland, NJ) in ice-cold PBS. The resulting
suspension was filtered through a 70-m cell strainer (BD Biosciences)
Bacterial Penetration of Bladder Epithelium through Lipid Rafts 18945
and collected by centrifugation. The pellet was resuspended in 1 ml of
carbonate buffer and homogenized by passing through a 21-gauge nee-
dle 20 times, sonicated in an ice bath for 5 min, and passaged through
a 21-gauge needle an additional 20 times. The sample was brought to
45% sucrose by the addition of an equal volume of 90% sucrose in MBS
and then overlaid with 2 ml each of 35 and 5% sucrose in MBS. The
gradient was centrifuged for 18 h at 39,000 rpm in a SW41Ti rotor, and
12 equal fractions (500 l each) were collected from the top of each
gradient and assayed for UPIa, caveolin-1, and clathrin heavy chain by
Western blotting using polyclonal anti-UPIa, polyclonal anti-caveolin-1,
or monoclonal anti-clathrin heavy chain (Transduction Laboratories)
antibodies.
Immunoprecipitation—Caveolin-1 and Rac1 were immunoprecipi-
tated from fraction 5 of the 5637 BEC lipid raft preparation as follows.
400 l of fraction 5 was brought to 1 ml with MBS (1% Nonidet P-40, 1
mM PMSF, and a 1:100 dilution of mammalian protease inhibitor mix-
ture). The sample was precleared with 10 g of normal rabbit IgG
(Santa Cruz Biotechnology) and 50 l of a 50% suspension of protein
G-Sepharose (Sigma) in MBS for 1 h at 4 °C. 4 g of polyclonal anti-
Rac1 (Santa Cruz Biotechnology) or polyclonal anti-caveolin-1 was
added, and the sample was incubated for 16 h at 4 °C. 50 l of a 50%
suspension of protein G-Sepharose was added, and the sample was
further incubated for 1 h at 4 °C. The immunoprecipitates were washed
three times with 1 ml of MBS (1% Nonidet P-40, 1 mM PMSF, and a
1:100 dilution of mammalian protease inhibitor mixture), resuspended
in 60 l of 2 Laemmli sample buffer, and boiled for 5 min. Immuno-
precipitates were assayed for Rac1 and caveolin-1 using monoclonal
anti-Rac1 or polyclonal anti-caveolin-1 antibodies.
Construction of Small Interfering RNA Vector, Transfection, and
Infection—To construct the small interfering RNA expression vector,
the pEGFP-N1 (BD Biosciences) backbone was used. Briefly,
pEGFP-N1 was digested by BglII and BamHI and was then re-ligated
to generate pEGFP-N1A. Human U6 small nuclear RNA promoter was
PCR-amplified from pTZ U6  1 (gift from John Rossi, Beckman Re-
search Institute of the City of Hope, Duarte, CA) with added HindIII
and BamHI sites at 5 and 3 ends, respectively. The PCR product was
cloned into pUC18 to generate pUC18-U6. The U6 promoter and its
flanking multiple cloning sites were PCR-amplified from pUC18-U6
with an added AflII site at both 5 and 3 ends. The PCR product was




TGAAGTTGACCAGGTCGATCTCCGG-3 were ordered from Integra-
ted DNA Technologies, Inc. Coralville, IA. The boldface and underlined
sequences are forward and reverse sequences, respectively, which cor-
respond to nucleotides 419–437 of the human cavolin-1 gene (Gen-
BankTM accession number NM-001753). Oligo1 and 2 were annealed to
form double-stranded DNA and cloned into pEGFP-N1A-U6 by using
BamHI and EcoRI sites to generate pSi-Cav419. pEGFP-N1A-U6 and
pSi-Cav419 were used to transfect human bladder cell line 5637 by
using LipofectAMINE 2000 (Invitrogen). Five days following transfec-
tion, the cells were plated onto 96-well plates and grown overnight,
followed by the invasion assay using E. coli ORN103(pSH2) as de-
scribed above. The transfected cells were also seeded onto glass cover-
slips and grown overnight, followed by paraformaldehyde fixation and
labeling for caveolin-1 with polyclonal anti-caveolin-1 and goat anti-
rabbit Alexa Fluor 660 F(ab)2 (Molecular Probes). Endogenous caveo-
lin-1 expression was examined using a Nikon Eclipse TE200 confocal
scanning light microscope. Whole cell lysates of 5-day post-transfection cells
were examined by Western blotting using polyclonal anti-caveolin-1 anti-
body as above or monoclonal anti--actin, clone AC-15 (Sigma), to control for
protein loading. Densitometry was performed using ImageJ software (Na-
tional Institutes of Health, rsb.info.nih.gov/ij/).
Electron Microscopy—Bladder epithelial cells grown on Transwell
filters were left uninfected or infected with E. coli ORN103(pSH2) for
4 h, washed to remove unbound bacteria, and fixed with 2% paraform-
aldehyde, 2% glutaraldehyde in PBS. The filters were processed for
TEM using standard methods. For the enumeration of caveolae, unin-
fected cells grown on Transwell filters and processed for TEM as above
were examined, and caveolae were enumerated as described previously
(30).
RESULTS
The 5637 Human BEC Line Expresses UPIa Protein—To
begin studying the aspects of E. coli BEC invasion, we utilized
a well established in vitro model, the 5637 human BEC line,
that has been shown to closely mimic E. coli/BEC interactions
in vivo (9, 11, 31–33). Although 5637 BEC have been used
previously, they were never shown to express the protein UPIa,
the in vivo host receptor for type 1 fimbriated E. coli (15). We
therefore examined 5637 BEC for the expression of UPIa.
Western blotting was performed on a whole cell lysate boiled in
2 Laemmli sample buffer, using a UPIa specific antibody. No
band of the expected size (27 kDa) was seen, but a much larger,
unclear band was observed, indicating that the protein may
have been aggregated by boiling in Laemmli sample buffer, as
reported previously for bovine UPI (Fig. 1A) (34). Another
whole cell lysate was prepared and allowed to remain at room
temperature for 30 min before SDS-PAGE and immunoblot-
ting, and a single band of the appropriate size was seen, dem-
onstrating that 5637 BEC express UPIa, the in vivo host cell
receptor for E. coli type 1 fimbriae (Fig. 1B).
Morphological Aspects of E. coli Invasion—Transmission elec-
tron microscopy (TEM) was performed on uninfected and infected
5637 BEC monolayers, grown on Transwell filters, to explore the
morphological aspects of E. coli invasion. Uninfected BEC were
observed to express distinct cave-like structures, called caveolae,
along their basolateral surface (218 basolateral caveolae/mm of
filter), but none were visible on their apical surface, consistent
with previous reports of polarized caveolae expression on other
epithelial cell lines (Fig. 1C) (30). On BEC infected with type 1
fimbriated E. coli, caveolae were now found at the apical surface,
intimately associated with invading bacteria at their point of
attachment and forming part of the phagosomal structure encas-
ing internalized bacteria (Fig. 1, D–F). As a means of further
demonstrating lipid raft association with intracellular E. coli, we
examined infected BEC using specific probes for the most com-
monly used markers of lipid rafts: caveolin-1, cholesterol, and the
glycolipid GM1 (23, 35, 36). Shown in Fig. 2, B, D, and F, are
fluorescent images showing the accumulation of caveolin-1, cho-
lesterol, and GM1, respectively, around intracellular E. coli. The
corresponding differential interference contrast images are
shown in Fig. 2, A, C, and E. We also employed a biochemical
approach to demonstrate mobilization of cellular caveolin-1 to sites
of intracellular bacteria. FITC-labeled E. coli ORN103(pSH2) were
incubated with BEC, after which the cells were homogenized and
fractionated on a sucrose gradient to isolate intracellular bacteria-
containing compartments as described previously (35). Each of the
various fractions was collected and probed for fluorescence. Most of
the fluorescence was associated with fractions 8–10, which repre-
sented extracellular bacteria (Fig. 2G). However, a small peak of
fluorescence, representing bacteria-containing phagosomes, was
detected in fraction 5. When fractions obtained from infected and
uninfected BEC were probed with caveolin-1-specific antibody on a
Western blot, the distribution of caveolin-1 was virtually identical
except in fraction 5 of the infected cells, where a noticeable shift in
cellular caveolin-1 to the location of intracellular bacteria was ob-
served (Fig. 2G). Taken together, the microscopic and biochemical
data point to the mobilization and colocalization of common lipid
raft markers at sites of intracellular E. coli.
Caveolin-1 Is Essential for Optimal E. coli Invasion of
BEC—If E. coli is utilizing lipid rafts for the invasion of BEC,
it stands to reason that certain lipid raft-associated proteins
would be required for entry through this pathway. Previously,
the lipid raft-associated protein caveolin has been shown to be
involved in the infection of host cells by various pathogens that
enter cells via lipid rafts (37, 38). To examine the role of
caveolin-1 protein in E. coli invasion of BEC, we utilized the
method of RNA interference (RNAi) to reduce caveolin-1 ex-
pression. A sequence fragment of human caveolin-1 was chosen
and inserted into an EGFP-expressing vector designed for use
in RNAi. Five days following transient transfection of BEC, the
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cells were examined microscopically for the expression of vec-
tor-encoded EGFP (green) and endogenous caveolin-1 (red) us-
ing a polyclonal anti-caveolin antibody. Fig. 3, A and B, show
vector (pEGFP-N1A-U6)-transfected cells showing EGFP ex-
pression and caveolin-1 labeling (Fig. 3A) or caveolin-1 labeling
alone (Fig. 3B). Note that even cells expressing high levels of
EGFP show no changes in caveolin-1 expression. Shown in Fig.
3, C and D, are RNAi construct (pSi-Cav419)-transfected cells
showing EGFP expression and caveolin-1 labeling (Fig. 3C) or
caveolin-1 labeling alone (Fig. 3D). Note the transfected,
EGFP-expressing cells marked with white arrows and the large
decrease of caveolin-1 expression seen in these cells (Fig. 3,
C–D). Caveolin-1 expression was quantified by Western blot-
ting and densitometry (Fig. 3E). When corrected for protein
loading by using the relative amounts of -actin in each sam-
ple, caveolin-1 expression was reduced by 38%, which corre-
sponded closely with the percentage of cells transfected with
pSi-Cav419 (34.3%) (transfection was 28.1% for the vector
pEGFP-N1A-U6). When compared with the greater than 50%
inhibition of E. coli invasion by transfecting with pSi-Cav419,
as determined by utilizing a gentamicin protection assay, this
indicates an important role for the lipid raft protein caveolin-1
in the process of BEC invasion by E. coli (Fig. 3F).
Rac1 Associates with Caveolin-1 in Lipid Rafts of BEC—
Many signaling molecules are known to be enriched within
lipid rafts (20, 23, 24), so we hypothesized that, if lipid rafts are
the path of BEC invasion for E. coli, signaling molecules in-
volved in E. coli invasion of BEC may also be located in lipid
rafts. The Rho family GTPase member Rac1 has been shown
recently (31) to play a vital role in the invasion of E. coli into
BEC. We sought to determine whether this signaling molecule,
essential to E. coli BEC invasion, was also localized to BEC
FIG. 1. 5637 human BEC express the E. coli type 1 fimbrial receptor, UPIa, and induction of caveolae by type 1 fimbriae-expressing
E. coli. A and B, UPIa-specific Western blot of a 5637 human BEC whole cell lysate in 2 Laemmli sample buffer either boiled (A) or incubated
at room temperature (B) for 30 min. Arrow in A points to high molecular weight UPIa aggregate. C, transmission electron micrograph showing
caveolae (arrows) on the basolateral surface of 5637 BEC. D–F, transmission electron micrographs of 5637 BEC infected with E. coli
ORN103(pSH2). Note the flask-shaped caveolae associated with bacteria attached to the surface (arrows in D–F) and with internalized bacteria
(arrows in F; see inset of F). An interesting structure (outlined by small arrows in E; see inset of E) associated with a bacterium in the early stages
of invasion may represent a ‘‘leading edge’’ of the internalization process.
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lipid rafts. We utilized a lipid raft isolation protocol to purify
lipid raft microdomains from uninfected 5637 BEC before and
after treatment with the compound MBCD, which extracts
cholesterol from the cells, disrupting lipid raft structure and
function (35, 36). Following sucrose density gradient centrifu-
gation, the majority of Rac1 (94% by densitometry) was lo-
cated in the lipid raft fractions (fractions 4–6), as defined by a
light buoyant density and the presence of the lipid raft marker
caveolin-1 (83% by densitometry) (Fig. 4A) (29, 39). Following
FIG. 2. Association of internalized type 1 fimbriae-expressing
E. coli with markers of lipid rafts. A–F, microscopic images showing
the association of caveolin-1 (B), cholesterol (D), and GM1 (F) with
internalized type 1 fimbriated E. coli and the corresponding differential
interference contrast images (A, C, and E). Arrowheads point to intra-
cellular bacteria, and arrows point to extracellular bacteria, which show
no labeling. G, anti-caveolin-1 Western blot (top) and fluorescence con-
tent (bottom) of fractions from sucrose density gradients of uninfected
bladder epithelial cells or cells infected with FITC-labeled E. coli
ORN103(pSH2).
FIG. 3. RNAi knockdown of caveolin-1 expression inhibits E.
coli invasion of BEC. A–D, confocal images of 5637 human BEC
transiently transfected with vector alone (pEGFP-N1A-U6) (A and B) or
RNAi construct (pSi-Cav419) (C and D). Shown in A and C is EGFP
(green) expression and caveolin-1 expression (red). Shown in B and D is
caveolin-1 expression (red) alone. White arrows in A and B show cells
highly transfected with pEGFP-N1A-U6 whose caveolin-1 expression is
not altered compared with nontransfected cells (white arrowhead).
White arrows in C and D show cells highly transfected with pSi-Cav419
whose caveolin-1 expression has been “knocked down.” Small arrow-
heads show moderately transfected cells, and large arrowheads point to
nontransfected cells. E, Western blot of 5-day post-transfection 5637
BEC showing relative amounts of -actin and caveolin-1. F, E. coli
ORN103(pSH2) invasion of 5637 BEC, 5 days after transfection with
pEGFP-N1A-U6 or pSi-Cav419. The values are expressed as a percent-
age of bacterial invasion of pEGFP-N1A-U6 transfected cells. * indi-
cates p  0.001 relative to pEGFP-N1A-U6 transfected cells as deter-
mined by Student’s t test.
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treatment with 10 mM MBCD for 1 h, there was a 78% decrease
in Rac1 localization and a 70% decrease in caveolin-1 localiza-
tion to the lipid raft fractions, showing that Rac1 lipid raft
localization is sensitive to lipid raft disruption. We further
examined the association between Rac1 and caveolin-1 through
immunoprecipitation studies of BEC lipid raft fractions. Caveo-
lin-1 was coprecipitated with Rac1-specific immunoprecipita-
tion and vice versa (Fig. 4B). We have now demonstrated that
a signaling molecule (Rac1) essential for E. coli invasion of BEC
is located in lipid rafts, implicating these structures as the
location where at least a part of the cellular signaling required
for E. coli BEC invasion is initiated. Together with the data
presented in Fig. 3, we have now demonstrated the lipid raft
localization of two separate proteins, caveolin-1 and Rac1, that
are required for the invasion of BEC by E. coli.
Disruptors and Usurpers of Lipid Rafts Block Entry of E. coli
into BEC—To demonstrate conclusively the involvement of
BEC lipid rafts in E. coli invasion, we examined the effect of
BEC lipid raft disruption on bacterial invasion. Following a
preinfection treatment of BEC with increasing concentrations
of MBCD, we observed a dose-dependent inhibition of E. coli
invasion (Fig. 5A), whereas no effect on the entry of L. mono-
cytogenes was seen. The invasive bacterium L. monocytogenes,
which does not normally colonize the bladder, was used solely
to demonstrate the specificity of MBCD for inhibiting E. coli
BEC invasion. Treatment of BEC with MBCD was also not
found to cause a decrease in the adherence of E. coli to BEC
(Fig. 5B). E. coli invasion was also inhibited by pretreatment
with nystatin, another disruptor of lipid rafts (Fig. 5A) (36, 40).
In addition, pretreatment of BEC with the B subunit of cholera
toxin, which enters cells through lipid rafts, thereby making
them unavailable to the infecting bacteria, also inhibited E. coli
invasion (Fig. 5A) (35, 41). Thus, specific disruption or occupa-
tion of BEC lipid rafts inhibits the entry of E. coli into human
BEC, conclusively demonstrating that E. coli are utilizing lipid
rafts as the portal of entry into BEC in vitro. We next sought to
confirm our results by demonstrating E. coli invasion of BEC
via lipid rafts in vivo, using a well established mouse model of
UTI (9, 10, 42).
Association of Uroplakin Ia with Lipid Rafts in the Mouse
Bladder—It has been hypothesized previously (25, 43) that for
microbial invasion via lipid rafts to occur, the host cell receptor
must either be located in lipid rafts or move to lipid rafts after
microbial attachment. We therefore sought to determine
whether the receptor for type 1 fimbriated E. coli on mouse
BEC, UPIa, was associated with lipid rafts by purifying lipid
raft microdomains from the bladders of BALB/c mice. The
majority of UPIa (81% by densitometry) is found in the light
buoyant density fractions (fractions 4–6) along with the lipid
raft protein caveolin-1 (59% by densitometry), well separated
from the heavy chain of clathrin, a non-lipid raft protein asso-
ciated with clathrin-coated pits, that is located in fractions 11
and 12 (Fig. 6A) (35). Thus, the BEC receptor for E. coli type 1
fimbriae has been isolated in the lipid raft fractions of the
mouse bladder, leading us to further study the role of lipid rafts
in mediating E. coli invasion of mouse BEC in vivo.
Inhibition of E. coli BEC Invasion in Vivo—We examined the
effect of lipid raft disruption on E. coli invasion of mouse BEC
by using the agent MBCD in a mouse UTI model (42). Uro-
pathogenic type 1 fimbriated E. coli J96 (28) suspended in 25
mM MBCD in PBS, or in PBS alone, was instilled into the
bladders of mice. After 1 h, the bladders were removed, bi-
sected, and incubated for 1 h in the presence of the antibiotic
gentamicin to kill extracellular bacteria. MBCD had no effect
on bacterial viability as determined by colony counts after a
60-min incubation in PBS with or without 25 mM MBCD.
MBCD treatment was found to inhibit markedly the invasion of
BEC by E. coli J96, but had no effect on the invasion of BEC by
the bacteria L. monocytogenes, which was again used as a
FIG. 5. Inhibiting invasion into human bladder epithelial cells
by disrupting or usurping the function of lipid rafts. A, E. coli
ORN103(pSH2) or L. monocytogenes invasion of bladder epithelial cells
before or after 30 min of treatment with MBCD, nystatin, or CTB. The
values are expressed as a percentage of bacterial invasion of untreated
cells. B, the adherence of E. coli ORN103(pSH2) to 5637 cells before and
after treatment of the cells with MBCD as determined by an MTT-based
adherence assay. * indicates p  0.001 relative to untreated controls as
determined by Student’s t test.
FIG. 4. The signaling molecule Rac1, required for E. coli BEC
invasion, is located in BEC lipid rafts. A, Rac1- or caveolin-1-
specific Western blot on fractions of uninfected 5637 human BEC iso-
lated by sucrose density fractionation before and after treatment with
MBCD. B, Rac1- or caveolin-1-specific Western blotting following Rac1-
or caveolin-1-specific immunoprecipitation performed on fraction 5 from
the sucrose density gradient as shown in A.
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control for the specificity of MBCD inhibition of E. coli BEC
invasion (Fig. 6, B and C). Thus, by disrupting mouse BEC lipid
rafts, we were able to specifically block the invasion of BEC by
E. coli, demonstrating that lipid rafts mediate E. coli BEC
invasion in vivo and implying a therapeutic potential for the
management of UTIs.
DISCUSSION
Uropathogens are thought to persist in a reservoir located in
the gastrointestinal tract and to initiate infection by being
introduced into the urethra (8). It is becoming apparent that
the bladder itself can serve as a reservoir, with the bacteria
invading the uroepithelium and persisting intracellularly in a
quiescent state, later reemerging to initiate another round of
infection (9–11). The findings presented here demonstrate by
morphological, biochemical, and functional analysis that E. coli
invasion of BEC utilizes host cell lipid rafts.
The involvement of lipid rafts in bacterial invasion of 5637
human BEC in vitro was first indicated by the intimate asso-
ciation seen between invading bacteria and host cell caveolae.
The expression of caveolae is normally restricted to the baso-
lateral surface of uninfected BEC, but invading E. coli were
seen to induce the formation of caveolar structures at sites of
bacterial attachment. The association of E. coli with caveolar
structures is somewhat reminiscent of the early stages of host
cell infection by simian virus 40 and echovirus 1, where viral
particles have been shown to interact with host cell caveolae by
TEM (38, 40). The association of lipid rafts with intracellular
bacteria was further demonstrated by fluorescent microscopy,
using specific probes for three commonly used markers of lipid
rafts, and by biochemical means, showing association between
bacteria-containing phagosomes and the lipid raft protein
caveolin-1. The association of lipid rafts markers with intracel-
lular E. coli in BEC is consistent with previous work demon-
strating microbial infection/invasion of host cells via lipid rafts
(25, 35, 36), and led us to examine the role of a known lipid raft
protein, caveolin-1, in E. coli invasion. Caveolin-1, which is
required for the formation of caveolar structures (30, 44), was
found to be required for the invasion of E. coli into BEC,
because inhibiting the expression of caveolin-1 by RNAi also
inhibited invasion of BEC by E. coli. The exact mechanism
FIG. 6. E. coli invades mouse BEC
via lipid rafts in a mouse model of
UTI. A, UPIa, caveolin-1, or clathrin
heavy chain-specific Western blotting of
mouse bladder fractions purified by su-
crose density fractionation. B and C, in-
vasion of BEC in a mouse model of UTI by
E. coli J96 (B) or L. monocytogenes (C) in
the presence or absence of 25 mM MBCD.
* indicates p  0.001 relative to mice in-
fected in the absence of MBCD as deter-
mined by Student’s t test. B and C, n  5
mice per group.
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through which caveolin-1 functions in this event is not known,
but this protein has been shown to interact with a number of
different signaling molecules and is tyrosine-phosphorylated
during certain signaling events (23, 24, 45). The Rho family
GTPase member Rac1, a signaling molecule involved in actin
polymerization and shown previously to be required for E. coli
BEC invasion, was also shown to be located in BEC lipid rafts
and was associated with caveolin-1 by immunoprecipitation.
Determining what effect this caveolin-1/Rac1 interaction has
on E. coli BEC invasion will require further study, but it has
been demonstrated that lipid raft localization is required for
proper stretch-induced Rac1 activation in cardiomyocytes (39).
The E. coli type 1 fimbrial receptor on BEC is the protein
UPIa (15), one of the four uroplakins that make up the scallop-
shaped urothelial plaques, which are thought to play an impor-
tant role in determining the permeability barrier presented by
the uroepithelium (14). In this report, we have demonstrated
for the first time an association between UPIa and biochemi-
cally purified lipid rafts isolated from mouse bladders, as well
as the MBCD inhibition of BEC invasion by E. coli in a mouse
model of UTI. The ability of type 1 fimbriated E. coli to invade
BEC appears to play a large role in the pathogenesis of UTIs as
well as the recurrence of these infections (9–11, 42). Under-
standing the role host cell lipid rafts play in the invasion of type
1 fimbriated E. coli into BEC would allow for a better under-
standing of how to break the cycle of infection and recurrence
so common to UTIs. A clinical correlation has been made be-
tween elevated serum cholesterol and an increased incidence of
UTI (46), which, along with our results, suggests that the use of
agents that modulate cellular cholesterol could play a role in
the management of UTIs. Indeed, many such agents, including
methyl--cyclodextrin, have already been safely used in hu-
mans (47).
It is important to note that the high impermeability of the
bladder epithelium is thought to be mediated not only by the
urothelial plaques but also by the specialized composition of
the lipids associated with them (14, 18–22). Thus, the urothe-
lial plaques and their associated lipid microdomains seem to
serve complementary roles in mediating the impressive imper-
meability of the bladder epithelium. We hypothesize that, par-
adoxically, E. coli is utilizing two mediators of uroepithelial
impermeability, namely the uroplakin particle (specifically
UPIa) and their associated cholesterol/sphingolipid enriched
microdomains to penetrate the bladder epithelium. The uro-
plakin particles themselves undergo physiological endocytosis
and exocytosis initiated by uroepithelial stretching and relax-
ation that occurs during normal filling and emptying of the
bladder (48, 49), and lipid rafts are known to contain the
molecular machinery required for endocytosis (50). It is not
known whether lipid rafts and associated molecules play some
role in the normal endocytosis/exocytosis of uroplakin particles,
but it now seems possible that E. coli could be usurping this
particular feature of uroplakin particles in a nonphysiological
manner to bypass the uroepithelial barrier.
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